The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...
The stock's fall snapped a two-day winning streak.
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.
2h
RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
AbbVie ABBV over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback